Table 1 Characteristics of patient-derived AML samples.
From: Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia
Sample | Age | Sex | Leuko | Blast(%) | Origin | Genetics |
|---|---|---|---|---|---|---|
PDX1 | 77.5 | F | 198 | 76 | PB | NPM, STAG2, DNMT3A |
PDX2 | 63.5 | F | 163 | 98 | PB | NPM1, TET2, DNMT3A |
PDX3 | 63.9 | F | 128 | 92 | PB | NPM1, DNMT3A, FLT3 |
PDX4 | 63.9 | M | 97 | 80 | PB | DNMT3A, FLT3, NPM1 |
PDX5 | 63.9 | F | 280 | 33 | PB | FLT3, DNMT3A, IDH2, SH2B3, NPM1 |
PDX6 | 64.1 | F | 176 | 90 | PB | FLT3, DNMT3A, IDH2, NPM1 |
PDX7 | 76.5 | M | 88 | 93 | PB | NRAS, NPM1, TET2 |
PDX8 | 52.5 | M | 55 | 91 | BM | t(6;11), PTPN11 |
